Last month the biopharmaceutical company Neurogene announced that they are pursuing a Rett syndrome gene replacement program.
Rachel McMinn, PhD, who serves as CEO, founded Neurogene in 2018, inspired by her experience with her brother, who lives with an undiagnosed neurological disease. That same year RSRT introduced Dr. McMinn to Stuart Cobb, PhD, who soon became the company’s Chief Scientific Officer.
RSRT has collaborated with both Neurogene and the University of Edinburgh for a number of years. Over the past decade, RSRT has provided almost $3 million to the University of Edinburgh to support Dr. Cobb’s research on gene replacement and RNA modification approaches to cure Rett syndrome.
Dr. McMinn and Dr. Cobb will join RSRT's CEO, Monica Coenraads, for a conversation with the Rett community. We hope you will join us to learn more about Neurogene’s program for Rett syndrome.